{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T23:31:30Z","timestamp":1768692690600,"version":"3.49.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.phrs.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T23:31:12Z","timestamp":1494718272000},"page":"14-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"PA","title":["Biased agonism\/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapy"],"prefix":"10.1016","volume":"125","author":[{"given":"Jennifer","family":"Maning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shmuel","family":"Negussie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Lymperopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.05.009_bib0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology XXIII. The angiotensin II receptors","volume":"52","author":"De Gasparo","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2017.05.009_bib0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molcel.2006.11.007","article-title":"New roles for \u03b2-arrestins in cell signaling: not just for seven-transmembrane receptors","volume":"24","author":"Lefkowitz","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2017.05.009_bib0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1126\/science.1109237","article-title":"Transduction of receptor signals by \u03b2-arrestins","volume":"308","author":"Lefkowitz","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.05.009_bib0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/pr.109.002436","article-title":"Beyond desensitization: physiological relevance of arrestin-dependent signaling","volume":"62","author":"Luttrell","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2017.05.009_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ncb3307","article-title":"\u03b2-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation","volume":"18","author":"Eichel","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature17198","article-title":"\u03b2-Arrestin biosensors reveal a rapid, receptor-dependent activation\/deactivation cycle","volume":"531","author":"Nuber","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2017.05.009_bib0035","doi-asserted-by":"crossref","first-page":"17201","DOI":"10.1074\/jbc.M910348199","article-title":"Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors","volume":"275","author":"Oakley","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0040","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cell.2016.07.004","article-title":"GPCR-G protein-\u03b2-arrestin super-complex mediates sustained G protein signaling","volume":"166","author":"Thomsen","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.05.009_bib0045","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.05.009_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone end-organ damage","volume":"113","author":"Marney","year":"2007","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.phrs.2017.05.009_bib0060","doi-asserted-by":"crossref","first-page":"H336","DOI":"10.1152\/ajpheart.01307.2005","article-title":"ANG II-induced cardiac molecular and cellular events: role of aldosterone","volume":"291","author":"Zhao","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0031-6997(25)06811-5","article-title":"Role of calcium and other mediators in aldosterone secretion from the adrenal glomerulosa cells","volume":"46","author":"Ganguly","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2017.05.009_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2003.12.020","article-title":"Adrenocortical cell lines","volume":"228","author":"Rainey","year":"2004","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nm1553","article-title":"Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure","volume":"13","author":"Lymperopoulos","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2017.05.009_bib0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molmed.2007.10.005","article-title":"Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation","volume":"13","author":"Lymperopoulos","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2017.05.009_bib0085","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.mt.6300371","article-title":"Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity","volume":"16","author":"Lymperopoulos","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2017.05.009_bib0090","doi-asserted-by":"crossref","first-page":"16378","DOI":"10.1074\/jbc.M109.077859","article-title":"Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction","volume":"285","author":"Lymperopoulos","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biocel.2016.02.003","article-title":"GPCRs of adrenal chromaffin cells & catecholamines: the plot thickens","volume":"77","author":"Lymperopoulos","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/pgs.11.178","article-title":"Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown","volume":"13","author":"Lymperopoulos","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2017.05.009_bib0105","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/me.2015-1305","article-title":"GRK2 upregulation creates a positive feedback loop for catecholamine production in chromaffin cells","volume":"30","author":"Jafferjee","year":"2016","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0110","doi-asserted-by":"crossref","first-page":"H2032","DOI":"10.1152\/ajpheart.00702.2009","article-title":"Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure","volume":"298","author":"Rengo","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0115","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/j.1476-5381.2012.01972.x","article-title":"Blockade of \u03b2-adrenoceptors restores the GRK2-mediated adrenal \u03b1(2)-adrenoceptor-catecholamine production axis in heart failure","volume":"166","author":"Rengo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4330\/wjc.v7.i9.539","article-title":"Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failure","volume":"7","author":"McCrink","year":"2015","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0125","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure: pathophysiology and therapy","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2017.05.009_bib0130","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1073\/pnas.0811706106","article-title":"An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo","volume":"106","author":"Lymperopoulos","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2017.05.009_bib0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jacc.2010.08.635","article-title":"Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels","volume":"57","author":"Lymperopoulos","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0140","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1126\/science.1134562","article-title":"Targeting of diacylglycerol degradation to M1 muscarinic receptors by b-arrestins","volume":"315","author":"Nelson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.05.009_bib0145","doi-asserted-by":"crossref","first-page":"23911","DOI":"10.1074\/jbc.M001553200","article-title":"The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras","volume":"275","author":"Rizzo","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0150","doi-asserted-by":"crossref","first-page":"41259","DOI":"10.1074\/jbc.M206595200","article-title":"Repression of DAX-1 and induction of SF-1 expression. Two mechanisms contributing to the activation of aldosterone biosynthesis in adrenal glomerulosa cells","volume":"277","author":"Osman","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0155","doi-asserted-by":"crossref","first-page":"14335","DOI":"10.1038\/ncomms14335","article-title":"Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2017.05.009_bib0160","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ajh.2012.47","article-title":"Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment","volume":"25","author":"Sarzani","year":"2012","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2017.05.009_bib0165","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.phrs.2017.05.009_bib0170","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","article-title":"Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats","volume":"40","author":"Naruse","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.05.009_bib0180","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.jacc.2014.09.070","article-title":"Different potencies of angiotensin receptor blockers at suppressing adrenal \u03b2-Arrestin1-dependent post-myocardial infarction hyperaldosteronism","volume":"64","author":"Lymperopoulos","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0185","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1038\/srep08116","article-title":"Suppression of adrenal (arrestin1-dependent aldosterone production by ARBs: head-to-head comparison","volume":"5","author":"Dabul","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2017.05.009_bib0190","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2017.05.009_bib0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2010.1949","article-title":"Association of candesartan vs losartan with all-cause mortality in patients with heart failure","volume":"305","author":"Eklind-Cervenka","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2017.05.009_bib0200","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jama.2012.452","article-title":"Association of treatment with losartan vs candesartan and mortality among patients with heart failure","volume":"307","author":"Svanstr\u00f6m","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.phrs.2017.05.009_bib0205","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2009.11.007","article-title":"The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis","volume":"16","author":"Shah","year":"2010","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.phrs.2017.05.009_bib0210","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.05.009_bib0215","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2017.05.009_bib0220","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cell.2015.04.011","article-title":"Structure of the angiotensin receptor revealed by serial femtosecond crystallography","volume":"161","author":"Zhang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.05.009_bib0225","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1074\/jbc.274.11.7103","article-title":"Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor","volume":"274","author":"Miura","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1747-0285.2006.00444.x","article-title":"Interactions between conserved residues in transmembrane helices 2 and 7 during angiotensin AT1 receptor activation","volume":"68","author":"Nikiforovich","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.phrs.2017.05.009_bib0235","doi-asserted-by":"crossref","first-page":"ra33","DOI":"10.1126\/scisignal.2002522","article-title":"Differential \u03b2-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs","volume":"5","author":"Zimmerman","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2017.05.009_bib0240","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1530\/JME-14-0125","article-title":"Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor","volume":"53","author":"Balakumar","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0245","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1021\/jm0103155","article-title":"Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments","volume":"45","author":"Wilkes","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0250","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1124\/mol.61.4.768","article-title":"Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors","volume":"61","author":"Holloway","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0255","first-page":"1706","article-title":"Association of b-arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carboxyl terminus and correlates with receptor internalization","volume":"15","author":"Qian","year":"2001","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/1568026043451375","article-title":"On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?","volume":"4","author":"Tzakos","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0265","doi-asserted-by":"crossref","first-page":"e00226","DOI":"10.1002\/prp2.226","article-title":"Structure-activity relationship study of angiotensin II analogs in terms of \u03b2-arrestin-dependent signaling to aldosterone production","volume":"4","author":"Valero","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.phrs.2017.05.009_bib0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.neuro.27.070203.144206","article-title":"Desensitization of G protein-coupled receptors and neuronal functions","volume":"27","author":"Gainetdinov","year":"2004","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2017.05.009_bib0275","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pharmthera.2008.11.005","article-title":"Physiological and pharmacological implication of beta-arrestin regulation","volume":"121","author":"Schmid","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2017.05.009_bib0280","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ijcard.2016.10.069","article-title":"New and old roles of the peripheral and brain renin-angiotensin-aldosterone-system (RAAS): focus on cardiovascular and neurological diseases","volume":"227","author":"Mascolo","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0285","doi-asserted-by":"crossref","first-page":"e70976","DOI":"10.1371\/journal.pone.0070976","article-title":"The effect of angiotensin II and angiotensin-(1\u20137) in the rostral ventrolateral medulla of rats on stress-induced hypertension","volume":"8","author":"Du","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2017.05.009_bib0290","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1357-2725(02)00306-0","article-title":"The brain renin-angiotensin system: location and physiological roles","volume":"35","author":"McKinley","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brainres.2016.04.059","article-title":"Regulation of angiotensinogen expression by angiotensin II in spontaneously hypertensive rat primary astrocyte cultures","volume":"1643","author":"Gowrisankar","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2017.05.009_bib0300","doi-asserted-by":"crossref","first-page":"25095","DOI":"10.1016\/S0021-9258(19)74575-X","article-title":"stimulates the synthesis of angiotensinogen in hepatocytes by inhibiting adenylylcyclase activity and stabilizing angiotensinogen mRNA","volume":"268","author":"Klett","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0305","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1471-4159.2011.07406.x","article-title":"Regulation of angiotensinogen by angiotensin II in mouse primary astrocyte cultures","volume":"119","author":"O\u2019Callaghan","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1742-7843.2007.00006.x","article-title":"Amiodarone induces angiotensinogen gene expression in lung alveolar epithelial cells through activation protein-1","volume":"100","author":"Uhal","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2017.05.009_bib0315","doi-asserted-by":"crossref","first-page":"16483","DOI":"10.1074\/jbc.270.28.16483","article-title":"The regulation of AP-1 activity by mitogen-activated protein kinases","volume":"270","author":"Karin","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.05.009_bib0320","doi-asserted-by":"crossref","first-page":"719.6","DOI":"10.1096\/fasebj.30.1_supplement.719.6","article-title":"Unexpected negative role of the AT1R adaptor protein \u03b2arrestin1 in the ERK1\/2 activation of SHR-derived primary astrocytes","volume":"30","author":"Negussie","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2017.05.009_bib0325","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/B978-0-12-394440-5.00012-7","article-title":"Arrestins in the cardiovascular system","volume":"118","author":"Lymperopoulos","year":"2013","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.phrs.2017.05.009_bib0330","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2015.05.019","article-title":"GPCR signaling and cardiac function","volume":"763","author":"Capote","year":"2015","journal-title":"Eur. J. Pharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817303523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817303523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T15:39:08Z","timestamp":1750261148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817303523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":66,"alternative-id":["S1043661817303523"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.05.009","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biased agonism\/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}